Mirella Memmi

List of Publications by Year
in descending order

28 papers	5,522 citations	361045 20 h-index	525886 27 g-index
30 all docs	30 docs citations	30 times ranked	4306 citing authors

#	Article	IF	Citations
1	Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2001, 103, 196-200.	1.6	1,291
2	Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2002, 106, 69-74.	1.6	1,103
3	FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death. Cell, 2003, 113, 829-840.	13.5	683
4	Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2006, 99, 292-298.	2.0	293
5	Brugada syndrome and sudden cardiac death in children. Lancet, The, 2000, 355, 808-809.	6.3	244
6	Novel Insight Into the Natural History of Short QT Syndrome. Journal of the American College of Cardiology, 2014, 63, 1300-1308.	1.2	191
7	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. Journal of the American College of Cardiology, 2016, 67, 1053-1058.	1.2	191
8	Clinical Phenotype and Functional Characterization of CASQ2 Mutations Associated With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2006, 114, 1012-1019.	1.6	189
9	Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. Journal of Cellular Physiology, 2002, 190, 1-6.	2.0	182
10	Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes. Journal of Biological Chemistry, 2001, 276, 30623-30630.	1.6	181
11	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. Journal of Clinical Investigation, 2002, 110, 1201-1209.	3.9	172
12	Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2540-2550.	1.2	148
13	Interplay Between Genetic Substrate, QTcÂDuration, and Arrhythmia Risk in Patients With Long QT Syndrome. Journal of the American College of Cardiology, 2018, 71, 1663-1671.	1.2	137
14	Novel Arrhythmogenic Mechanism Revealed by a Long-QT Syndrome Mutation in the Cardiac Na+Channel. Circulation Research, 2001, 88, 740-745.	2.0	114
15	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1748-H1756.	1.5	88
16	Mechanisms of I _{Ks} suppression in LQT1 mutants. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3003-H3011.	1.5	68
17	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. Journal of the American College of Cardiology, 2020, 75, 1772-1784.	1.2	44
18	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. Human Mutation, 2018, 39, 1835-1846.	1.1	31

#	Article	IF	Citations
19	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. Circulation, 2020, 142, 513-515.	1.6	31
20	Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression.. Journal of Medical Genetics, 1998, 35, 778-783.	1.5	29
21	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Î²-Blockers. JAMA Cardiology, 2022, 7, 504.	3.0	26
22	Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT). European Journal of Human Genetics, 2014, 22, 152-152.	1.4	18
23	Concentrations of l-dopa in plasma and plasma ultrafiltrates. Journal of Pharmaceutical and Biomedical Analysis, 1996, 14, 1043-1046.	1.4	17
24	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, .	2.1	14
25	Challenges in Molecular Diagnostics of Channelopathies in the Next-Generation Sequencing Era: Less Is More?. Frontiers in Cardiovascular Medicine, 2016, 3, 29.	1.1	8
26	Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy. Heart Rhythm, 2021, 18, 1698-1706.	0.3	2
27	Mutation site-specific risk profile in patients with Type 1 Long QT Syndrome. European Heart Journal, 2020, 41, .	1.0	0
28	Role of CACNA1C variants in Brugada syndrome: clinical aspects and genetic testing strategies. European Heart Journal, 2020, 41, .	1.0	0